TAKEDA PHARMACEUTICAL CO LTD's ticker is TAK and the CUSIP is 874060205. A total of 304 filers reported holding TAKEDA PHARMACEUTICAL CO LTD in Q2 2023. The put-call ratio across all filers is 0.21 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $52,220 | +9.4% | 3,376 | +11.1% | 0.02% | +6.2% |
| Q2 2023 | $47,749 | +6.6% | 3,039 | +11.8% | 0.02% | +14.3% |
| Q1 2023 | $44,799 | +5.6% | 2,718 | 0.0% | 0.01% | 0.0% |
| Q4 2022 | $42,407 | +21.2% | 2,718 | +0.4% | 0.01% | 0.0% |
| Q3 2022 | $35,000 | -7.9% | 2,707 | +0.5% | 0.01% | 0.0% |
| Q2 2022 | $38,000 | -2.6% | 2,694 | 0.0% | 0.01% | 0.0% |
| Q1 2022 | $39,000 | +5.4% | 2,694 | 0.0% | 0.01% | +7.7% |
| Q4 2021 | $37,000 | -71.3% | 2,694 | -65.8% | 0.01% | -74.5% |
| Q3 2021 | $129,000 | +3.2% | 7,873 | +6.2% | 0.05% | -21.5% |
| Q2 2021 | $125,000 | -1.6% | 7,411 | +6.9% | 0.06% | -9.7% |
| Q1 2021 | $127,000 | +10.4% | 6,934 | +9.2% | 0.07% | 0.0% |
| Q4 2020 | $115,000 | -25.8% | 6,348 | -27.1% | 0.07% | -36.8% |
| Q3 2020 | $155,000 | -0.6% | 8,708 | +0.1% | 0.11% | -8.1% |
| Q2 2020 | $156,000 | +83.5% | 8,698 | +56.9% | 0.12% | +45.9% |
| Q1 2020 | $85,000 | – | 5,543 | – | 0.08% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Adelphi Capital LLP | 8,958,784 | $176,757,000 | 33.75% |
| Ovata Capital Management Ltd | 879,800 | $17,557,092,000 | 13.04% |
| Paulson & Co. | 13,244,711 | $261,318,000 | 5.64% |
| Glenview Capital Management | 30,582,721 | $603,397,000 | 5.28% |
| MIC CAPITAL PARTNERS (PUBLIC) (US) IM, LLC | 718,028 | $14,167,000 | 4.85% |
| Velanne Asset Management Ltd | 302,694 | $5,972,000 | 3.52% |
| Blackcrane Capital, LLC | 172,708 | $3,408,000 | 2.72% |
| Melqart Asset Management (UK) Ltd | 1,557,000 | $30,720,000 | 2.57% |
| GMT CAPITAL CORP | 3,345,976 | $66,016,000 | 2.55% |
| REDWOOD CAPITAL MANAGEMENT, LLC | 827,955 | $16,336,000 | 2.24% |